ReviewBiomarker research2018
Molecular landscape and targeted therapy of acute myeloid leukemia.
Review in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1/Tim-3 blockade.Cell death & disease · 2026Article
- Challenges in Differential Diagnosis of Diffuse Gingival Enlargement: Report of Two Representative Cases and Literature Review.Dentistry journal · 2024Article
- Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030.Journal of global health · 2024Article
- Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.Saudi journal of biological sciences · 2024Article
- Serum albumin is associated with the inherent property of acute myeloid leukemia and correlates with patient outcomes.Blood science (Baltimore, Md.) · 2024Article
- Ribosome profiling: a powerful tool in oncological research.Biomarker research · 2024Review
- Prognostic value of an eighteen-genes panel in acute myeloid leukemia by analyzing TARGET and TCGA databases.Cancer biomarkers : section A of Disease markers · 2023Article
- Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia.Cancers · 2022Article
- Article
- A forward selection algorithm to identify mutually exclusive alterations in cancer studies.Journal of human genetics · 2021Article
- Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.American journal of blood research · 2021Review
- RNA sequencing: new technologies and applications in cancer research.Journal of hematology & oncology · 2020Review
- Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.Asia-Pacific journal of clinical oncology · 2020Review
- The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017.Journal of hematology & oncology · 2020Article
- Expression patterns of immune checkpoints in acute myeloid leukemia.Journal of hematology & oncology · 2020Article
- Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.Cancer gene therapy · 2020Article
- Advances in targeted therapy for acute myeloid leukemia.Biomarker research · 2020Review
- Development of a highly sensitive method for detection of FLT3D835Y.Biomarker research · 2020Article
- Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.Biomarker research · 2020Article
- CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.Journal of hematology & oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For decades, genetic aberrations including chromosome and molecular abnormalities are important diagnostic and prognostic factors in acute myeloid leukemia (AML). ATRA and imatinib have been successfully used in AML and chronic myelogenous leukemia, which proved that targeted therapy by identifying molecular lesions could improve leukemia outcomes. Recent advances in next generation sequencing have revealed molecular landscape of AML, presenting us with many molecular abnormalities. The individual prognostic information derived from a specific mutation could be modified by other molecular lesions. Therefore, the genomic complexity in AML poses a huge challenge to successful translation into more accurate risk stratification and targeted therapy. Herein, a summary of these mutations and targeted therapies are described. We focus on the prognostic information of recent identified molecular lesions and emerging targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.